ZA975942B - Non-aqueous protic peptide formulations. - Google Patents

Non-aqueous protic peptide formulations.

Info

Publication number
ZA975942B
ZA975942B ZA9705942A ZA975942A ZA975942B ZA 975942 B ZA975942 B ZA 975942B ZA 9705942 A ZA9705942 A ZA 9705942A ZA 975942 A ZA975942 A ZA 975942A ZA 975942 B ZA975942 B ZA 975942B
Authority
ZA
South Africa
Prior art keywords
peptide formulations
aqueous protic
protic peptide
aqueous
formulations
Prior art date
Application number
ZA9705942A
Other languages
English (en)
Inventor
Cynthia L Stevenson
Sally A Tao
Steven J Prestrelski
James B Eckenhoff
Jeremy C Wright
Joe Leonard
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of ZA975942B publication Critical patent/ZA975942B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
ZA9705942A 1996-07-03 1997-07-03 Non-aqueous protic peptide formulations. ZA975942B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2112996P 1996-07-03 1996-07-03

Publications (1)

Publication Number Publication Date
ZA975942B true ZA975942B (en) 1998-04-16

Family

ID=21802501

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9705942A ZA975942B (en) 1996-07-03 1997-07-03 Non-aqueous protic peptide formulations.

Country Status (27)

Country Link
EP (1) EP0909175B1 (xx)
JP (3) JP2001504802A (xx)
CN (1) CN1231256C (xx)
AR (1) AR008060A1 (xx)
AT (1) ATE241997T1 (xx)
AU (1) AU737664B2 (xx)
BR (1) BR9710130A (xx)
CA (1) CA2259403A1 (xx)
CO (1) CO4890854A1 (xx)
CZ (1) CZ433898A3 (xx)
DE (1) DE69722620T2 (xx)
DK (1) DK0909175T3 (xx)
ES (1) ES2201306T3 (xx)
HU (1) HUP9903942A3 (xx)
ID (1) ID19165A (xx)
IL (1) IL127769A (xx)
MY (1) MY121684A (xx)
NO (1) NO323933B1 (xx)
NZ (1) NZ333580A (xx)
PL (1) PL189402B1 (xx)
PT (1) PT909175E (xx)
RO (1) RO119862B1 (xx)
RU (1) RU2203085C2 (xx)
SK (1) SK284490B6 (xx)
TW (1) TW491703B (xx)
WO (1) WO1998000152A1 (xx)
ZA (1) ZA975942B (xx)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69722620T2 (de) * 1996-07-03 2004-04-29 Alza Corp., Palo Alto Nicht-waessrige protische peptidzubereitungen
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
ES2298378T3 (es) 2001-06-28 2008-05-16 Novo Nordisk A/S Formulacion estable de glp-1 modificado.
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
JP4734236B2 (ja) * 2003-04-25 2011-07-27 ボストン サイエンティフィック サイムド，インコーポレイテッド 固形型の薬物の貯蔵及び制御された放出のための装置及びその製造方法
RU2421238C2 (ru) * 2003-11-20 2011-06-20 Ново Нордиск А/С Пептидная композиция, содержащая пропиленгликоль, являющаяся оптимальной для изготовления и применения в инъекционных устройствах
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
KR101106510B1 (ko) 2006-05-30 2012-01-20 인타르시아 세라퓨틱스 인코포레이티드 투피스, 내부채널 삼투압 전달 시스템 유동 조절기
DK2049081T3 (da) 2006-08-09 2013-02-25 Intarcia Therapeutics Inc Osmotiske leveringssystemer og stempelarrangementer
AU2013203271B2 (en) * 2007-01-19 2016-05-12 Hananja Ehf Methods and compositions for the delivery of a therapeutic agent
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
DK2121025T3 (en) * 2007-01-19 2017-01-30 Hananja Ehf Methods and compositions for delivering a therapeutic agent
ES2402172T3 (es) 2007-04-23 2013-04-29 Intarcia Therapeutics, Inc Formulación en suspensión de péptidos insulinotrópicos y usos de los mismos
HUE043228T2 (hu) 2007-06-22 2019-08-28 Univ Texas Stabil szubmikron peptid vagy protein részecskék képzése vékonyfilm fagyasztással
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
EP2315571A4 (en) * 2008-07-16 2013-05-01 Surmodics Pharmaceuticals Inc METHOD FOR PRODUCING MICROPARTICLES WITH BIOACTIVE PEPTIDES
HUE049023T2 (hu) 2008-08-15 2020-08-28 Ironwood Pharmaceuticals Inc Linaklotidot tartalmazó, szájon át történõ beadásra szolgáló készítmények
CA2743789C (en) 2008-11-16 2017-10-31 Board Of Regents, The Univesity Of Texas System Low viscosity highly concentrated suspensions
WO2011017502A2 (en) 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Linaclotide-containing formulations for oral administration
CN107638562B (zh) 2009-09-28 2022-12-02 精达制药公司 基本稳态药物递送的快速建立和/或终止
UA108636C2 (xx) 2010-02-17 2015-05-25 Пептид
RS59978B1 (sr) 2010-08-11 2020-03-31 Ironwood Pharmaceuticals Inc Stabilne formulacije linaklotida
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
DK2776055T3 (en) 2011-08-17 2017-03-06 Ironwood Pharmaceuticals Inc TREATMENTS FOR GASTROINTESTINAL DISORDERS
EP2659902A1 (en) * 2012-04-30 2013-11-06 Sun Pharmaceutical Industries Limited Leuprolide injection
WO2014124096A1 (en) * 2013-02-06 2014-08-14 Perosphere Inc. Stable glucagon formulations
EP2823808A1 (en) * 2013-07-09 2015-01-14 Ipsen Pharma S.A.S. Pharmaceutical composition for a sustained release of lanreotide
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
BR112018073511A2 (pt) 2016-05-16 2019-03-26 Intarcia Therapeutics, Inc. polipeptídeos seletivos do receptor de glucagon e métodos de uso dos mesmos
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
MX2019008006A (es) 2017-01-03 2019-08-29 Intarcia Therapeutics Inc Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco.
EP3372224A1 (en) 2017-03-07 2018-09-12 Alrise Biosystems GmbH New controlled drug delivery system using water miscible solvents for production of drug loaded micro- and nanoparticles
PE20211202A1 (es) 2017-08-24 2021-07-05 Novo Nordisk As Composiciones de glp-1 y sus usos
WO2021144476A1 (en) 2020-02-18 2021-07-22 Novo Nordisk A/S Pharmaceutical formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897256A (en) * 1986-11-25 1990-01-30 Abbott Laboratories LHRH analog formulations
ATE99543T1 (de) * 1987-10-15 1994-01-15 Syntex Inc Pulverfoermige zubereitungen zur intranasalen verabreichung von polypeptiden.
IT1237197B (it) * 1989-11-16 1993-05-26 Sclavo Spa Formulazioni farmaceutiche anidre e forme di dosaggio per la somministrazione rettale di calcitonina.
AU5018693A (en) * 1992-09-21 1994-04-12 Upjohn Company, The Sustained-release protein formulations
NZ262634A (en) * 1993-02-23 1997-02-24 Genentech Inc Stabilizing polypeptides against degradation by organic solvents by admixing the peptide with trehalose or mannitol
US5955430A (en) * 1993-09-24 1999-09-21 University Of Southern California Use of angiotensin II fragments and analogs thereof in tissue repair
JP3597233B2 (ja) * 1993-10-21 2004-12-02 久光製薬株式会社 経鼻組成物及びそれを含有する経鼻製剤
DE69722620T2 (de) * 1996-07-03 2004-04-29 Alza Corp., Palo Alto Nicht-waessrige protische peptidzubereitungen

Also Published As

Publication number Publication date
AR008060A1 (es) 1999-12-09
SK284490B6 (sk) 2005-05-05
MY121684A (en) 2006-02-28
IL127769A (en) 2006-10-31
ATE241997T1 (de) 2003-06-15
DK0909175T3 (da) 2003-09-29
CN1231256C (zh) 2005-12-14
ID19165A (id) 1998-06-28
CA2259403A1 (en) 1998-01-08
NO986209L (no) 1998-12-30
TW491703B (en) 2002-06-21
CO4890854A1 (es) 2000-02-28
NZ333580A (en) 2000-06-23
ES2201306T3 (es) 2004-03-16
JP2001504802A (ja) 2001-04-10
AU737664B2 (en) 2001-08-30
NO323933B1 (no) 2007-07-23
JP2008195739A (ja) 2008-08-28
HUP9903942A3 (en) 2000-07-28
PT909175E (pt) 2003-10-31
HUP9903942A2 (hu) 2000-04-28
NO986209D0 (no) 1998-12-30
AU3407397A (en) 1998-01-21
RO119862B1 (ro) 2005-05-30
CN1224356A (zh) 1999-07-28
BR9710130A (pt) 1999-08-10
DE69722620D1 (de) 2003-07-10
DE69722620T2 (de) 2004-04-29
JP2010043105A (ja) 2010-02-25
EP0909175B1 (en) 2003-06-04
SK179998A3 (en) 1999-05-07
PL189402B1 (pl) 2005-08-31
RU2203085C2 (ru) 2003-04-27
PL330869A1 (en) 1999-06-07
WO1998000152A1 (en) 1998-01-08
EP0909175A1 (en) 1999-04-21
CZ433898A3 (cs) 1999-04-14
IL127769A0 (en) 1999-10-28

Similar Documents

Publication Publication Date Title
ZA975942B (en) Non-aqueous protic peptide formulations.
ZA975941B (en) Non-aqueous polar aprotic peptide formulations.
ZA9710429B (en) Broad-spectrumδ-endotoxins.
GB9627091D0 (en) An inverted E antenna
GB2332660B (en) Improved deflector
ZA972186B (en) Lytic peptides.
HK1057643A1 (en) Time switch.
ZA97928B (en) Novel heteroaryl-oxazolidinones.
GB2311689B (en) Bandwidth bidding
ZA971466B (en) Endothelin-receptor-antagonists.
ZA978477B (en) Cysteine containing peptides.
GB9613705D0 (en) Novel peptides
ZA971474B (en) Endothelin-receptor-antagonists.
ZA979237B (en) Terminal block.
ZA973697B (en) Sprinkler.
GB9612054D0 (en) The spazzle (spacial puzzle)
GB9626362D0 (en) Peptides
GB9606765D0 (en) Peptides
GB9605904D0 (en) Peptides
GB9625227D0 (en) Peptides
SG55039A1 (en) Peptides
GB9612648D0 (en) Peptides
GB9608430D0 (en) Peptides
ZA975037B (en) Peptide derivatives.
ZA971534B (en) Peptide derivatives.